HSK16149
Phase 3Small molecule
Haisco Pharmaceutical Group Co., Ltd.HSK16149 is one of 96 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
3
Indications
10
Total Trials
2
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
212 competitors in Neuropathic Pain
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaPhase 3
Namenda
AbbViePhase 3
Briviact
UCBPhase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Sativex
Jazz PharmaceuticalsPhase 3
Ultram
WWim Janssens
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Phase 3
Marcaine
IInnocoll
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuralgia3 trials
Neuropathic Pain3 trials
Postherpetic Neuralgia1 trial
Interaction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HSK16149. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details